Cadrenal Therapeutics, Inc. (CVKD): who owns it and who trades it
As of Oct 30, 2026, CVKD insiders reported 23 open-market sales worth $458K and no purchases in the last 12 months, with 85% of the sale value made under pre-set 10b5-1 plans. The largest seller was Quang X Pham (CEO), with $388K.
Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, CVKD insiders reported $0 of open-market purchases and $458K of sales. 85% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Quang X Pham | CEO | Sale plan | 7,400 | $3.03 | $22.4K | Form 4 |
| Jun 26, 2026 | Quang X Pham | CEO | Sale plan | 9,029 | $3.05 | $27.5K | Form 4 |
| Jun 25, 2026 | Quang X Pham | CEO | Sale plan | 2,127 | $3.00 | $6.4K | Form 4 |
| Jun 23, 2026 | Quang X Pham | CEO | Sale plan | 2,277 | $3.20 | $7.3K | Form 4 |
| Jun 22, 2026 | Quang X Pham | CEO | Sale plan | 9,167 | $3.55 | $32.5K | Form 4 |
| Jun 17, 2026 | Quang X Pham | CEO | Sale plan | 513 | $3.16 | $1.6K | Form 4 |
| Jun 16, 2026 | Quang X Pham | CEO | Sale plan | 3,613 | $3.18 | $11.5K | Form 4 |
| Jun 15, 2026 | Quang X Pham | CEO | Sale | 3,666 | $3.58 | $13.1K | Form 4 |
| Jun 12, 2026 | Quang X Pham | CEO | Sale | 12,996 | $3.94 | $51.2K | Form 4 |
| Jun 11, 2026 | Quang X Pham | CEO | Sale | 1,462 | $4.12 | $6K | Form 4 |
| Jun 10, 2026 | Quang X Pham | CEO | Sale plan | 3,500 | $4.21 | $14.7K | Form 4 |
| Jun 9, 2026 | Quang X Pham | CEO | Sale plan | 12,992 | $4.06 | $52.7K | Form 4 |
| Jun 8, 2026 | Quang X Pham | CEO | Sale plan | 5,893 | $4.38 | $25.8K | Form 4 |
| Jun 5, 2026 | Quang X Pham | CEO | Sale plan | 2,064 | $4.42 | $9.1K | Form 4 |
| Jun 4, 2026 | Quang X Pham | CEO | Sale plan | 3,898 | $4.41 | $17.2K | Form 4 |
| Jun 3, 2026 | Quang X Pham | CEO | Sale plan | 2,323 | $4.26 | $9.9K | Form 4 |
| Jun 2, 2026 | Quang X Pham | CEO | Sale plan | 349 | $4.46 | $1.6K | Form 4 |
| May 29, 2026 | Quang X Pham | CEO | Sale plan | 303 | $5.01 | $1.5K | Form 4 |
| May 28, 2026 | Quang X Pham | CEO | Sale plan | 2,989 | $4.93 | $14.7K | Form 4 |
| May 22, 2026 | Quang X Pham | CEO | Sale plan | 1,165 | $5.69 | $6.6K | Form 4 |
| May 12, 2026 | Quang X Pham | CEO | Sale plan | 3,298 | $5.28 | $17.4K | Form 4 |
| May 11, 2026 | Quang X Pham | CEO | Sale plan | 6,476 | $5.76 | $37.3K | Form 4 |
| Dec 29, 2025 | Matthew K Szot | CFO | Sale plan | 9,933 | $6.97 | $69.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Quang X Pham | CEO and Chairman, Director, 10% owner | – | $388K | Jun 29, 2026 |
| Matthew K Szot | Chief Financial Officer | – | $69.2K | Dec 29, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CVKD short interest
Moderate short interest. 6.5% of CVKD shares are sold short: about 1 share in 15. Over the last 12 reports the number of shares short went up 225%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 230,655 CVKD shares were sold short, 6.5% of the shares outstanding, down 18.0% from the report before. At the average daily volume of 66,328 shares, buying them all back would take about 3.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 230,655 | 6.47% | -18% | 66,328 | 3.5 |
| Oct 15, 2026 | 281,405 | 7.89% | +166% | 310,361 | 1.0 |
| Sep 30, 2026 | 105,945 | 2.97% | -11% | 98,169 | 1.1 |
| Sep 15, 2026 | 118,800 | 3.33% | +37% | 225,284 | 1.0 |
| Aug 31, 2026 | 86,862 | 2.43% | +33% | 2.00M | 1.0 |
| Aug 14, 2026 | 65,083 | 1.82% | +7% | 36,140 | 1.8 |
| Jul 31, 2026 | 61,103 | 2.44% | +10% | 52,729 | 1.2 |
| Jul 15, 2026 | 55,656 | 2.22% | -32% | 117,234 | 1.0 |
| Jun 30, 2026 | 82,016 | 3.27% | +13% | 67,530 | 1.2 |
| Jun 15, 2026 | 72,278 | 2.88% | +5% | 78,561 | 1.0 |
| May 29, 2026 | 68,650 | 2.74% | -3% | 55,563 | 1.2 |
| May 15, 2026 | 70,928 | 2.83% | +31% | 70,442 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Cadrenal Therapeutics company events
Cadrenal Therapeutics filed 22 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership). The latest was on Oct 7, 2026.
- Oct 7, 2026AnnouncementThe Company issued a press release announcing that its Board of Directors has authorized the Company to initiate a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio. Filing
- Sep 29, 2026LeadershipCadrenal Therapeutics, Inc., held its 2026 Annual Meeting of Stockholders. Filing
- Aug 31, 2026AnnouncementThe Company issued a press release announcing positive feedback from a Type D Meeting with the FDA held on July 28, 2026. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 21, 2026AnnouncementThe Company issued a press release announcing a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise and the initiation of a structured process to secure strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its… Filing
- Jul 17, 2026LeadershipCadrenal Therapeutics, Inc. entered into a confidential separation agreement and general release, dated as of July 9, 2026, with James J. Ferguson III, the Company’s Chief Medical Officer. Filing
- Jul 10, 2026LeadershipJames J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc., advised the Board of Directors of the Company of his decision to resign from his position as Chief Medical Officer of the Company, effective July 31, 2026. Filing
- Jul 1, 2026AgreementCadrenal Therapeutics, Inc., a Delaware corporation, entered into a securities purchase agreement with an institutional investor, pursuant to which the Company sold and issued, in a private placement priced at-the-market under Nasdaq rules: (i) pre-funded warrants to purchase up to 960,000 shares… Filing
- Jun 29, 2026LeadershipThe Board of Directors of Cadrenal Therapeutics, Inc. appointed John P. Sharp as Interim Chief Financial Officer of the Company. Filing
- Jun 18, 2026AnnouncementThe Company issued a press release announcing its plans to submit a RPDD request to the FDA for tecarfarin as a treatment for pediatric patients with Kawasaki disease who develop coronary artery aneurysms and require chronic oral anticoagulation. Filing
- Jun 3, 2026LeadershipCadrenal Therapeutics, Inc. and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 30, 2026AnnouncementThe Company issued a press release announcing the completion of its End-of-Phase 2 meeting with the FDA and the receipt of guidance on key elements of the Phase 3 pivotal trial for CAD-1005, the Company’s investigational first-in-class 12-LOX inhibitor for HIT. The meeting with the FDA provided… Filing
- Apr 1, 2026AgreementCadrenal Therapeutics, Inc. entered into a warrant inducement letter agreement with a holder of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share, issued in a private placement offering that closed on November 4, 2024. Filing
- Mar 31, 2026ResultsReleased financial results. Filing
- Mar 12, 2026AnnouncementThe Company issued a press release highlighting pre-clinical research demonstrating the potential of its first-in-class 12-LOX inhibitor, CAD-1005, to target inflammatory consequences of obesity and Type 2 diabetes. Filing
- Feb 24, 2026AnnouncementCadrenal Therapeutics, Inc. issued a press release announcing results from a Phase 2 trial evaluating CAD-1005 (formerly VLX-1005) in patients with heparin-induced thrombocytopenia, a severe pro-thrombotic reaction to heparin, the most commonly used parenteral anticoagulant. Filing
- Dec 23, 2025AnnouncementCadrenal Therapeutics, Inc., a Delaware corporation,, filed a prospectus supplement with the U.S. Securities and Exchange Commission in connection with the Company’s “at the market offering” program for the offer and sale of up to $1.77 million of shares of the Company’s common stock, par value… Filing
- Dec 16, 2025AgreementCadrenal Therapeutics, Inc., a Delaware corporation, entered into a securities purchase agreement with certain investors named on the signature pages thereto. Filing
- Dec 11, 2025AgreementCadrenal Therapeutics, Inc., a Delaware corporation entered into an Asset Purchase Agreement with Veralox Therapeutics Inc., a Delaware corporation pursuant to which Seller sold all or substantially all of its right title and interest in assets owned or otherwise used or held for use by Seller in… Filing
- Dec 1, 2025LeadershipThe Board of Directors of Cadrenal Therapeutics, Inc. appointed Lee Scott Golden, M.D., to serve as a Class II director of the Company to hold office until the 2027 annual meeting of stockholders, at which time his term of office shall expire and a Class II director shall be elected for a full term… Filing
- Nov 18, 2025AnnouncementCadrenal Therapeutics, Inc., a Delaware corporation,, filed a prospectus supplement with the U.S. Securities and Exchange Commission in connection with the Company’s “at the market offering” program for the offer and sale of up to $3.44 million of shares of the Company’s common stock, par value… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cadrenal Therapeutics financials
Questions about Cadrenal Therapeutics, Inc. (CVKD) stock
Are CVKD insiders buying or selling?
In the last 12 months, CVKD insiders reported no open-market purchases and 23 sales worth $458K. The latest trade was on Jun 29, 2026. See every trade.
What is the short interest in CVKD?
As of Oct 30, 2026, 230,655 CVKD shares were sold short, 6.5% of the shares outstanding, down 18.0% from the report before. At the average daily volume of 66,328 shares, buying them all back would take about 3.5 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.